Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease

C. Fonarow, Gregg; Keech, Anthony; R. Pedersen, Terje; P. Giugliano, Robert; S. Sever, Peter; Lindgren, Peter; van Hout, Ben; Villa, Guillermo; Qian, Yi; Somaratne, Ransi; S. Sabatine, Marc

doi:10.1001/jamacardio.2017.2762

Public

Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease

Published in JAMA Cardiology • Aug 25, 2017

Authors:

Gregg C. Fonarow

Anthony Keech

Terje R. Pedersen

Abstract

Importance: The proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab has been demonstrated to reduce the composite of myocardial infarction, stroke, or cardiovascular death in patients with established atherosclerotic cardiovascular disease. To our knowledge, long-term cost-effectivene...

Subject

Evolocumab

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!